Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Sells Lexiva, Agenerase Royalties For $160M

This article was originally published in The Pink Sheet Daily

Executive Summary

Non-core assets bring in cash for HCV push and more.
Advertisement

Related Content

Vertex's Latest Finance Play: Selling Off EU Milestone Payments For Telaprevir
Vertex's Latest Finance Play: Selling Off EU Milestone Payments For Telaprevir
2008 Deals Of The Year
2008 Deals Of The Year
Potential HCV Blockbuster, Strong Fundraising Place Vertex In Enviable Position
Once Xenophobic, Big Pharma Looks Outside For Financing R&D
Schering-Plough Lays Out Phase III Plan For HCV Therapy Boceprevir
CVT gets $175M For Half Of Lexiscan Royalties
Vertex Kicks Off Telaprevir Pivotal Trial Next Month
Vertex Kicks Off Telaprevir Pivotal Trial Next Month

Topics

Advertisement
UsernamePublicRestriction

Register

PS068007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel